Pulse Biosciences (PLSE) Competitors $15.72 +0.50 (+3.29%) Closing price 04:00 PM EasternExtended Trading$15.72 -0.01 (-0.03%) As of 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PLSE vs. SLNO, TMDX, INSP, NVST, PRCT, WRBY, LIVN, EYE, NVCR, and LMATShould you be buying Pulse Biosciences stock or one of its competitors? The main competitors of Pulse Biosciences include Soleno Therapeutics (SLNO), TransMedics Group (TMDX), Inspire Medical Systems (INSP), Envista (NVST), PROCEPT BioRobotics (PRCT), Warby Parker (WRBY), LivaNova (LIVN), National Vision (EYE), NovoCure (NVCR), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry. Pulse Biosciences vs. Its Competitors Soleno Therapeutics TransMedics Group Inspire Medical Systems Envista PROCEPT BioRobotics Warby Parker LivaNova National Vision NovoCure LeMaitre Vascular Soleno Therapeutics (NASDAQ:SLNO) and Pulse Biosciences (NASDAQ:PLSE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership. Which has more risk & volatility, SLNO or PLSE? Soleno Therapeutics has a beta of -2.63, meaning that its stock price is 363% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500. Do institutionals and insiders hold more shares of SLNO or PLSE? 97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by company insiders. Comparatively, 71.5% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is SLNO or PLSE more profitable? Pulse Biosciences' return on equity of -68.44% beat Soleno Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Soleno TherapeuticsN/A -77.52% -63.44% Pulse Biosciences N/A -68.44%-58.17% Which has higher earnings and valuation, SLNO or PLSE? Pulse Biosciences has higher revenue and earnings than Soleno Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno TherapeuticsN/AN/A-$175.85M-$4.62-18.51Pulse Biosciences$700K1,510.69-$53.58MN/AN/A Does the media favor SLNO or PLSE? In the previous week, Soleno Therapeutics had 12 more articles in the media than Pulse Biosciences. MarketBeat recorded 14 mentions for Soleno Therapeutics and 2 mentions for Pulse Biosciences. Soleno Therapeutics' average media sentiment score of 0.88 beat Pulse Biosciences' score of 0.47 indicating that Soleno Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soleno Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulse Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend SLNO or PLSE? Soleno Therapeutics presently has a consensus target price of $108.70, suggesting a potential upside of 27.10%. Pulse Biosciences has a consensus target price of $22.00, suggesting a potential upside of 39.95%. Given Pulse Biosciences' higher probable upside, analysts plainly believe Pulse Biosciences is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Pulse Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPulse Biosciences beats Soleno Therapeutics on 7 of the 13 factors compared between the two stocks. Get Pulse Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PLSE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLSE vs. The Competition Export to ExcelMetricPulse BiosciencesMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.02B$6.58B$5.52B$9.32BDividend YieldN/A1.30%4.25%4.05%P/E RatioN/A25.4928.1519.68Price / Sales1,510.6967.67438.33100.29Price / CashN/A20.0535.5357.53Price / Book8.414.668.235.67Net Income-$53.58M$174.76M$3.23B$257.51M7 Day Performance-2.90%-1.13%-0.01%0.52%1 Month Performance2.54%1.21%5.61%8.84%1 Year Performance-18.46%2.34%26.52%14.18% Pulse Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLSEPulse Biosciences3.7274 of 5 stars$15.72+3.3%$22.00+39.9%-22.0%$1.02B$700K0.00140SLNOSoleno Therapeutics4.5906 of 5 stars$82.76+1.5%$108.70+31.3%+66.5%$4.17BN/A-17.9130High Trading VolumeTMDXTransMedics Group2.2582 of 5 stars$116.88+3.9%$125.13+7.1%-19.9%$3.95B$441.54M85.94210Positive NewsAnalyst ForecastINSPInspire Medical Systems4.8615 of 5 stars$130.17-0.1%$211.91+62.8%-7.8%$3.84B$802.80M59.981,246News CoveragePositive NewsAnalyst ForecastNVSTEnvista3.3655 of 5 stars$20.05-0.8%$20.23+0.9%+24.2%$3.40B$2.51B-3.0712,300Analyst RevisionPRCTPROCEPT BioRobotics2.4813 of 5 stars$58.17+2.7%$87.50+50.4%-13.2%$3.22B$249.12M-34.22430News CoverageAnalyst ForecastAnalyst RevisionWRBYWarby Parker2.445 of 5 stars$23.02+3.7%$22.88-0.6%+40.5%$2.41B$795.09M-191.803,780Positive NewsLIVNLivaNova3.074 of 5 stars$43.97-0.8%$59.29+34.8%-16.5%$2.40B$1.25B-10.752,900News CoveragePositive NewsEYENational Vision2.8452 of 5 stars$25.01+2.2%$22.10-11.6%+99.2%$1.98B$1.82B-75.7913,411NVCRNovoCure3.5306 of 5 stars$17.42-1.0%$32.43+86.2%-6.7%$1.94B$605.22M-11.541,488LMATLeMaitre Vascular2.6164 of 5 stars$84.09+0.5%$97.83+16.3%-4.7%$1.90B$226.26M42.47490News CoveragePositive News Related Companies and Tools Related Companies SLNO Competitors TMDX Competitors INSP Competitors NVST Competitors PRCT Competitors WRBY Competitors LIVN Competitors EYE Competitors NVCR Competitors LMAT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLSE) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredTrump has to finance $21 trillion. Here’s His Move…Trump needs $21 trillion to fund his agenda — and insiders believe he’s quietly preparing a major shift in the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulse Biosciences, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulse Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
